Wedbush analyst Robert Driscoll lowered the firm’s price target on Day One Biopharmaceuticals to $33 from $35 and keeps an Outperform rating on the shares. The firm notes Day One Biopharmaceuticals reported Q4 results, as it continues to prepare for commercial launch of tovorafenib. Wedbush sees a high likelihood of tovorafenib approval, given the compelling FIREFLY-1 data, and an underappreciated commercial opportunity.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DAWN:
- Day One Biopharmaceuticals price target lowered to $40 from $45 at Piper Sandler
- A New Cause for Concern: Day One Biopharmaceuticals, Inc. Adds a New Regulation Risk
- Day One price target lowered to $35 from $45 at JonesResearch
- Day One Biopharmaceuticals Updates Corporate Presentation
- Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
